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The binding of the Epstein-Barr virus glycoprotein gp350 by complement receptor type 2 (CR2) is critical for
viral attachment to B lymphocytes. We set out to test hypotheses regarding the molecular nature of this
interaction by developing an enzyme-linked immunosorbent assay (ELISA) for the efficient analysis of the
gp350-CR2 interaction by utilizing wild-type and mutant forms of recombinant gp350 and also of the CR2
N-terminal domains SCR1 and SCR2 (designated CR2 SCR1-2). To delineate the CR2-binding site on gp350,
we generated 17 gp350 single-site substitutions targeting an area of gp350 that has been broadly implicated in
the binding of both CR2 and the major inhibitory anti-gp350 monoclonal antibody (MAb) 72A1. These
site-directed mutations identified a novel negatively charged CR2-binding surface described by residues
Glu-21, Asp-22, Glu-155, Asp-208, Glu-210, and Asp-296. We also identified gp350 amino acid residues involved
in non-charge-dependent interactions with CR2, including Tyr-151, Ile-160, and Trp-162. These data were
supported by experiments in which phycoerythrin-conjugated wild-type and mutant forms of gp350 were
incubated with CR2-expressing K562 cells and binding was assessed by flow cytometry. The ELISA was further
utilized to identify several positively charged residues (Arg-13, Arg-28, Arg-36, Lys-41, Lys-57, Lys-67, Arg-83,
and Arg-89) within SCR1-2 of CR2 that are involved in the binding interaction with gp350. These experiments
allowed a comparison of those CR2 residues that are important for binding gp350 to those that define the
epitope for an effective inhibitory anti-CR2 MAb, 171 (Asn-11, Arg-13, Ser-32, Thr-34, Arg-36, and Tyr-64). The
mutagenesis data were used to calculate a model of the CR2-gp350 complex using the soft-docking program
HADDOCK.
Epstein-Barr virus (EBV; human herpesvirus type 4) is a
member of the herpesvirus family and is found in a large
proportion (90%) of the world’s population. While child-
hood EBV infection often is clinically silent, delayed infection
until adolescence or later can result in the development of
infectious mononucleosis. In immunodeficient individuals,
EBV also has been linked to malignancies or disease states
including African Burkitt’s lymphoma, nasopharyngeal carci-
noma, EBV-associated lymphoproliferative disease, non-
Hodgkin’s lymphoma, and oral hairy leukoplakia (6). EBV
primarily infects two main cell types, B lymphocytes and epi-
thelial cells, although under some circumstances the virus also
can infect T cells, natural killer cells, smooth muscle cells, and
astrocytes (27, 35). In B cells, the interaction between EBV
and the cell surface is initially mediated by the predominant
glycoprotein in the viral envelope, gp350/220, binding to com-
plement receptor type 2 (CR2/CD21) (9, 10, 22, 31, 33, 41).
Fusion with the cell membrane and the invasion of the host cell
then is facilitated by the binding of a second viral glycoprotein,
gp42, to HLA class II molecules and also by three additional
viral glycoproteins, gB, gH, and gL (14, 15, 19, 28). Soluble
forms of both CR2 and gp350 have been shown to inhibit the
EBV invasion of peripheral blood mononuclear cells and B
lymphocytes, respectively (32, 41). In addition, monoclonal
antibodies (MAbs) generated against gp350 have been shown
to effectively inhibit the infection of peripheral B lymphocytes
with EBV (42), and some forms of this protein have been
shown to act successfully as a vaccine against EBV-associated
diseases in animal models and in human clinical trials (20, 25,
38). While recombinant EBV gp350 deletion strains have been
shown to be capable of transforming human B lymphocytes,
they do so with a significantly reduced efficiency (21), and there
is little doubt that the interaction between CR2 and gp350 is
the primary mechanism by which EBV is adsorbed to the cell
surface.
EBV gp350/220 is an extensively glycosylated polypeptide
(907 residues) that is expressed as two alternatively spliced
forms of approximately 350 and 220 kDa (4). The three-di-
mensional structure of a truncated form of gp350 comprising
the amino-terminal 470 residues has been elucidated by X-ray
crystallography at a 3.5-Å resolution (40). Three distinct do-
mains were identified (residues 4 to 153, 165 to 305, and 317 to
426), each comprising an anti-parallel -barrel structure and
joined by two linker regions, each of 11 amino acid residues.
These domains are packed tightly against each other, forming
a distinctive L-shaped arrangement that is almost uniformly
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glycosylated (Fig. 1A). A limited multiple-site mutagenesis
study, targeting a glycan-free area of gp350, suggested a puta-
tive CR2-binding site within a negatively charged region of this
molecule that incorporates the two N-terminal domains and
the linker region connecting them (residues 154 to 164) (40).
Those mutations affecting CR2 binding also disrupted the abil-
ity of gp350 to be recognized by its major neutralizing MAb,
72A1. These data are consistent with two separate peptide
mapping analyses that have identified a number of linear se-
quences of gp350 that are involved in EBV binding to CR2.
These sequences are in close proximity to, or directly overlap
with, the CR2-binding region identified from the mutagenesis
and crystal studies (30, 43).
CR2 is a member of the regulators of the complement ac-
tivation family of proteins (24). Members of this family are
characterized by the presence of short repeating domains com-
prising approximately 60 amino acids, known as short consen-
sus repeats (SCR) or complement control protein modules
(37). Each of these compact units contains conserved residues
including four cysteines and a nearly invariant tryptophan. The
molecular structure of CR2 comprises a 15- or 16-SCR extra-
cellular domain and short transmembrane and cytoplasmic re-
gions. In addition to gp350, physiologically relevant ligands of
CR2 (reviewed in reference 16) include proteolytic fragments
of complement component C3, including C3d, C3dg, and iC3b
(23, 45), alpha interferon (1, 7), and the low-affinity immuno-
globulin E receptor CD23 (2, 3). The structures of CR2 N-
terminal domains SCR1 and SCR2 (designated CR2 SCR1-2),
in both free and C3d-complexed forms, have been determined
by X-ray crystallography (34, 39). In both cases CR2 SCR1-2
adopts a compact conformation in which the two SCR domains
are packed against each other, forming a tight V shape (Fig.
1B). Whether the tightly packed conformation of these do-
mains as seen in the crystal structures reflects their conforma-
tion under native conditions is debatable; an analytical ultra-
centrifugation and X-ray scattering study carried out in
conjunction with constrained modeling indicated that CR2
SCR1-2 is more extended in solution than it is in the crystals
(11). Recently, we identified residues in CR2 that are involved
in the ligation of gp350 by employing flow cytometry to mea-
sure the binding of recombinant wild-type gp350 to K562
erythroleukemia cells transfected with wild-type, or single-site
mutant, full-length forms of CR2 (46). Our data suggested that
gp350 binding is mediated primarily by positively charged res-
idues within SCR1 of CR2.
The goal of the current work was to accumulate sufficient
data to underpin the reliable knowledge-based docking of an
SCR1-2-gp350 complex by significantly increasing the available
mutagenesis data. To achieve this, we developed an enzyme-
linked immunosorbent assay (ELISA)-based analysis in which
wild-type or mutant forms of SCR1-2 of CR2 were expressed
as maltose-binding protein (MBP) fusion proteins using Esch-
erichia coli. To minimize disruption to potential long-range
electrostatic charge effects that have previously been associ-
ated with CR2-ligand interactions (29, 47), we decided to pur-
sue an alanine substitution mutagenesis strategy, with only a
single additional serine-to-proline mutation being generated.
To delineate the corresponding CR2-binding site on gp350, we
also employed an alanine-screening approach, targeting resi-
dues within the two N-terminal domains of gp350 and the
connecting linker region using the ELISA described above.
This ELISA-based characterization of the CR2-binding site on
gp350 was verified by employing wild-type CR2-expressing
K562 cells to measure the binding of our gp350 point mutants
using flow cytometry. The resulting sets of ELISA- and cell-
based mutagenesis data were utilized to generate a series of
ambiguous interaction restraints (AIRs) that then were used to
calculate a model of the CR2–gp350 complex (8). The valida-
tion of the model was provided by experiments in which our
MBP-CR2 mutant library was used to characterize the struc-
tured epitope for an anti-CR2 MAb, 171, which strongly in-
hibits all known CR2-ligand interactions (1, 13, 46). Our data
clearly show that the epitope for the 171 MAb on CR2 directly
overlaps with a region of CR2 that interacts with the surface of
the gp350 molecule.
MATERIALS AND METHODS
Production of the anti-CR2 MAbs 171 and 629. Anti-CR2 MAbs 171 and 629
were obtained from the spent culture medium of hybridoma cells grown in RPMI
1640 supplemented with 2 mM L-glutamine, 100 IU penicillin, 100 g/ml strep-
tomycin, and 10% fetal bovine serum. Antibodies were purified by affinity chro-
matography using protein G Sepharose 4 fast flow resin (GE Healthcare Bio-
sciences Corp.) according to the manufacturer’s instructions. Purified MAbs 171
and 629 subsequently were exchanged into phosphate-buffered saline (PBS), pH
7.4 (containing 136.9 mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl, 1.5 mM
KH2PO4), and finally were concentrated to give a stock solution containing 1
mg/ml of antibody as determined by UV-visible spectrophotometry, and the
product was stored at 20°C until needed.
Expression of wild-type and mutant MBP-CR2 SCR1-2 recombinant proteins
in Escherichia coli. DNA corresponding to residues 1 to 133 of wild-type CR2
(SCR1-2) was PCR amplified and then ligated into the prokaryotic expression
vector pMAL-p2x (New England Biolabs), which encodes a maltose-binding
protein (MBP) tag at the 5 end of the inserted DNA, as previously described
(46). Plasmid DNA subsequently was transformed into E. coli BL21 cells, and
FIG. 1. Schematic ribbon representations of (A) EBV gp350 and
(B) CR2 SCR1-2, as determined by X-ray crystallography. (A) The
secondary structure of the gp350 fragment corresponding to residues 4
to 443 of the native sequence of gp350 (B95-8 strain) is shown in green.
Indicated are the three independent -barrel domains comprising the
major structural components: D1, corresponding to residues 4 to 153;
D2 (residues 165 to 305); and D3 (residues 317 to 426). Also indicated
are two structured linker regions, designated linker-1 (residues 154 to
164) and linker-2 (residues 306 to 316), connecting D1 and D2 as well
as D2 and D3, respectively. A total of 14 glycan moieties identified in
the crystal structure also are indicated in blue. (PDB accession code
2H6O) (40). (B) The secondary structure of the two amino-terminal
domains (SCR1-2) of CR2 as identified in the cocrystal structure of the
CR2-C3d complex are shown in cyan. Each SCR domain comprises
five short -strands and four cysteine residues forming disulfide bonds
at either end of the domain. Indicated are SCR1 (residues 1 to 62),
SCR2 (residues 71 to 129), and the linker region connecting both
domains (residues 63 to 70) (PDB accession code 1GHQ) (39). N-
term, N terminus; C-term, C terminus.
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wild-type recombinant MBP-CR2 SCR1-2 was produced according to earlier
protocols (46). To summarize, recombinant wild-type MBP-CR2 SCR1-2 protein
was expressed from overnight cultures induced with isopropyl--D-thiogalacto-
side. Cultures then were harvested by centrifugation, and the resulting pellets
were resuspended in a column buffer containing 20 mM Tris-HCl, pH 7.4, 0.2 M
NaCl, 1 mM EDTA, and lysed by sonication. The lysate was clarified by centrif-
ugation and then purified by successive affinity (amylose resin; New England
Biolabs) and size-exclusion (Hiload S200 26/60; GE Biosciences) chromatogra-
phy stages.
Recombinant L10A, N11A, R13A, S15P, Y16A, R28A, S32A, T34A, R36A,
K41A, K50A, K57A, Y64A, K67A, Y68A, R83A, T86A, R89A, and M117A
forms of CR2 SCR1-2 DNA were produced from wild-type MBP-CR2 SCR1-2
DNA by utilizing a QuikChange site-directed mutagenesis kit (Stratagene) ac-
cording to the manufacturer’s instructions. Plasmid DNA containing the mutant
CR2 SCR1-2 insert then was transformed into E. coli BL21, and recombinant
mutant CR2 SCR1-2 proteins were expressed and purified as described above.
Expression of recombinant gp350 proteins. EBV genomic DNA was extracted
from previously obtained cell supernatants of the marmoset B95-8 leukocyte cell
line (ATCC) using a QIAamp UltraSens virus kit (Qiagen) as described previ-
ously (46). DNA corresponding to residues 1 to 470 of EBV gp350/220 and a
fragment of the E. coli biotin carboxyl carrier protein (BCCP) corresponding to
residues 70 to 156 were separately PCR amplified. PCR fragments then were
ligated into the pSecTag2/Hygro B eukaryotic expression vector (Invitrogen),
which encodes a myc epitope and a hexahistidine tag at the 3 end of the inserted
DNA. Plasmid DNA subsequently was transfected into human embryonic kidney
293f freestyle cells (Invitrogen) for the soluble expression of recombinant EBV
gp350 into the medium. Resulting recombinant gp350 was concentrated and
concurrently exchanged into a sodium phosphate column buffer for purification
purposes. Recombinant gp350 protein was purified by utilizing successive immo-
bilized metal affinity and size-exclusion chromatography steps. After being pu-
rified, gp350 either was aliquoted and then frozen at 70°C until required for
ELISA or was biotinylated (gp350-biotin) using biotin ligase (Avidity). The
resulting gp350-biotin was conjugated to phycoerythrin (PE)-NeutrAvidin (Mo-
lecular Probes), generating fluorochrome-tagged gp350 monomers for dual-color
flow cytometric binding analysis.
Mutant forms of gp350 were generated to target a number of residues located
within domain 1 (D1) and domain 2 (D2) of gp350 and also the 11-residue linker
region (linker-1) connecting the two domains. Residues Glu-21, Asp-22, Asp-53,
Glu-119, Tyr-151, Glu-155, Tyr-159, Ile-160, Trp-162, Asp-163, Glu-201, Asp-
208, Glu-210, Glu-214, Asp-215, Glu-236, and Glu-296 were selected for alanine-
screening studies to delineate the CR2-binding site on the gp350 molecule and
also to characterize the nature of the interaction between the two molecules.
Single-site mutant forms of recombinant EBV gp350 were produced from wild-
type B95-8 gp350 DNA by utilizing a QuikChange site-directed mutagenesis kit
(Stratagene) according to the manufacturer’s instructions. Recombinant mutant
gp350 proteins were expressed and purified as described above for the wild type.
CR2-gp350, CR2-171 MAb, and CR2-629 MAb ELISAs. Plates were coated
overnight at 4°C with 5 g/ml of gp350, MAb 171, or MAb 629 in 20 mM sodium
bicarbonate buffer, pH 8.8. After being coated, the plates were blocked using
0.1% bovine serum albumin (BSA) in a PBS solution, pH 7.4, for 1 h at room
temperature. The plates then were washed and incubated with either wild-type or
mutant MBP-CR2 SCR1-2 at concentrations ranging from 0.03125 to 2.0 g/ml
in PBS for 1 h at room temperature. After further washes, wild-type or mutant
MBP-CR2 binding was detected using commercially available horseradish per-
oxidase-conjugated anti-MBP MAb (New England Biolabs) according to the
manufacturer’s instructions.
Flow cytometry. Flow cytometric experiments were carried out using K562
erythroleukemia cells transfected with full-length wild-type CR2 as described
previously (17, 46). Binding analyses were carried out using wild-type or mutant
forms of gp350-biotin. For each condition, 5 105 human CR2-transfected K562
cells first were incubated with anti-CR2 HB5 MAb at 1 g/ml on ice for 1 h. The
HB5-coated cells subsequently were incubated with fluorescein isothiocyanate
(FITC)-conjugated goat anti-mouse polyclonal antibody (BD Biosciences) at 1
g/ml on ice for 30 min. The primary epitope for HB5 has been identified within
the N-terminal SCR3-4 domains of CR2 and accordingly does not interfere with
ligand binding. During this incubation, 100 l of gp350-biotin monomers in
PBS–0.1% BSA–0.01% sodium azide were prepared for each condition by add-
ing 0.5 g of recombinant wild-type or mutant gp350-biotin and 0.4 g PE-
conjugated NeutrAvidin (Molecular Probes) and incubating them at room tem-
perature for 30 min. Following the washing of the FITC-stained K562 cells, 100
l of monomeric PE-conjugated gp350-biotin was added to each sample of cells
and incubated for 30 min on ice. After being washed, the cells were fixed and
analyzed by multicolor flow cytometry in the University of Colorado Cancer
Center Flow Cytometry Core Facility (Denver). Cells were analyzed as previ-
ously described, with gating on either whole-cell populations and/or the inter-
mediate 25% of CR2-expressing cells (FITC positive). Wild-type or mutant
gp350-biotin binding was determined by PE mean channel fluorescence. A min-
imum of three separate experiments was carried out for each mutation.
Generation by HADDOCK of a CR2-gp350 model. Mutagenesis data from
these and previous studies were used to derive a series of models of the CR2-
gp350 complex utilizing version 1.3 of the soft-docking program HADDOCK (8).
This employs a knowledge-based approach by which the program utilizes exper-
imentally derived data, in conjunction with the available structures, to drive the
docking of two macromolecules. Residues that have been experimentally impli-
cated in a binding interaction and that are therefore likely to form part of the
interface between two molecules are designated active. In this case, active resi-
dues for each molecule were defined as those residues that our mutagenesis data
have identified as playing a significant role in the binding interaction between
CR2 and EBV (46) and that possessed a main chain or side chain solvent
accessibility of 50% or greater (as determined by the program NACCESS (S.
Hubbard and J. Thornton). Selected active residues for CR2 were Arg-13, Ser-
15, Arg-28, Lys-41, Lys-67, and Arg-83. For gp350, the selected active residues
were Glu-21, Tyr-151, Glu-155, Ile-160, Trp-162, Asp-208, Glu-210, and Asp-296.
Also used in the HADDOCK calculations are passive residues, defined as those
residues in close proximity to active residues with high main chain or side chain
solvent accessibility. This information is introduced in the form of AIRs
consisting of calculated distance restraints between any atom within the active
residues of one protein and all atoms within the active and passive residues
on the respective binding partner (8). Standard analyses were performed by
HADDOCK on 100 water-refined structures from an initial 2,000 structures
calculated and include an analysis of the energy contributions from buried
surface area and electrostatic interactions.
RESULTS
Single-site mutations were generated within the domains of
EBV gp350 and human CR2, which mediate the interaction
between these proteins, and were subjected to a functional
assay. The aim was to accumulate sufficient data to accurately
delineate the binding surfaces and to drive a reliable soft-
docking exercise resulting in a robust model of the complex.
MBP-CR2 SCR1-2-gp350 mutant ELISA. To characterize
the CR2 SCR1-2-binding site on gp350, we generated single-
site substitutions targeting a glycan-free area of this molecule
that was broadly implicated in CR2-ligand binding by previous
crystal-driven multiple-site mutagenesis studies and, sepa-
rately, by peptide mapping studies (30, 43, 46). Our alanine
substitutions targeted residues within the two N-terminal
-barrel domains (D1, residues 4 to 153; and D2, residues 165
to 305) and the 11-residue linker region that connects them
(linker-1).
Within D1 of gp350, E21A (in the crystal structure of gp350
identified as Asp-21), D22A, and Y151A showed significant
(greater than 20%) decreases in CR2 SCR1-2 binding relative
to that of wild-type gp350, while D53A and E119A exhibited
approximately wild-type-like levels of binding (Fig. 2, Table 1).
Within linker-1 of gp350 we generated single-site mutations
targeting those residues tentatively implicated as contributing
to the gp350-CR2 interaction in a previous multiple-site mu-
tagenesis study (40). The current single-substitution mutagen-
esis data identified Ile-160 and Trp-162 (which form part of the
previously described multiple-site mutations) as well as Glu155
(which does not) as key players in the ligation of MBP-CR2
SCR1-2 to gp350, since all were unable to bind significant
levels of CR2. On the other hand, Y159A and D163A mutant
forms of gp350 retained the ability to bind wild-type-like levels
of CR2 (Table 1).
Within D2, a double-site opposite-charge substitution tar-
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geting residues Asp-208 and Glu-210 (D208R/E210R) was pre-
viously shown to inhibit the binding of gp350 to CR2 and also
to disrupt the epitope for MAb 72A1 (40). These data were
used to direct alanine-screening experiments targeting residues
Glu-201, Asp-208, Glu-210, Glu-214, Asp-215, Glu-236, and
Asp-296. Plate-bound forms of E201A, D208A, E210A,
D215A, and D296A exhibited a decreased ability to bind MBP-
CR2 SCR1-2 (Fig. 2). The remaining D2-based mutants gen-
erated in the current study, E214A and E236A, which are
spatially close to each other, exhibited no significant decreases
in their capacity to bind MBP-CR2 SCR1-2 (Table 1).
Mapping the results of the gp350 mutant ELISA onto the
crystal structure of gp350 reveals a single binding surface for
CR2 SCR1-2 on the rigid -barrel domains comprising D1 and
D2 (Fig. 3). This region is dominated by negatively charged
residues. However, additional contributions to the CR2-bind-
ing interaction are provided by residues within linker-1. These
include some significant non-charge-dependent interactions
arising from Ile-160 and Trp-162.
EBV gp350-biotin–K562 erythroleukemia cell-binding as-
say. K562 erythroleukemia cells expressing wild-type CR2 ini-
tially were incubated with the noninhibitory anti-CR2 MAb
HB5 and subsequently were FITC-labeled by incubation with
FITC-conjugated goat anti-mouse immunoglobulin G. They
then were assessed for their capacity to bind PE-conjugated
wild-type or mutant forms of gp350-biotin using flow cytom-
etry. For the most part, the data obtained were in excellent
agreement with the MBP-CR2 SCR1-2-gp350 ELISA results
described above (Fig. 4, Table 1). For example, D21A, E22A,
Y151A, E155A, I160A, W162A, D208A, E210A, and D296A
FIG. 2. MBP-CR2 SCR1-2–gp350 ELISA data targeting residues within gp350. The abilities of MBP-CR2 SCR1-2 to bind plate-bound mutant
forms of gp350 (E21A, D22A, Y151A, E155A, I160A, W162A, E201A, D208A, E210A D215A, and D296A) are shown. The averages and standard
errors of the means of the normalized values relative to those of wild-type gp350 binding are given. Data are not shown for a number of gp350
mutants that exhibited wild-type-like (20% reduction) binding: D53A, E119A, Y159A, D163A, E214A, and E236A (Table 1).
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mutant forms of gp350-biotin all exhibited decreases (20%)
in their capacity to bind to full-length CR2 SCR1-15, although
the decrease in binding was less marked than that observed by
ELISA. Again, consistently with the ELISA analysis, D53A,
E119A, Y159A, D163A, and E236A mutant forms of gp350-
biotin demonstrated wild-type-like levels of binding. Three of
the 17 mutants tested, E201A, E214A, and D215A, were ex-
ceptions in that they displayed differing levels of binding to
those observed in the ELISA analysis: E201A and D215A both
retained wild-type-like levels of binding (103.4 and 86.5%,
respectively), while E214A (76.2%) exhibited only a slight vari-
ation in binding from the wild-type-like binding curve seen in
the ELISA.
MBP-CR2 SCR1-2 mutant–gp350 ELISA. Mutations within
the two N-terminal SCR domains of CR2 were selected on the
basis of previous experimental work that implicated certain
residues as being important in EBV or gp350 binding (26, 46).
The strategy also was influenced by the fact that SCR1 of CR2
is characterized by a large number of positively charged resi-
dues, and the interaction between CR2 and gp350 has been
demonstrated to be charge dependent in nature (12, 36). In the
current work, mutations directed at residues Arg-13 (R13A),
Arg-28 (R28A), Arg-36 (R36A), Lys-41 (K41A), and Lys-57
(K57A) resulted in the significantly decreased capacity of re-
combinant MBP-CR2 SCR1-2 to bind gp350 (Fig. 5, Table 2).
In addition, a single mutation targeting Ser-15 (S15P) within
the first intercysteine region of SCR1 (chosen on the basis of a
comparison to the mouse orthologue of CR2) also resulted in
a major reduction in gp350 binding. Additional mutations tar-
geting Leu-10 (L10A), Asn-11 (N11A), Tyr-16 (Y16A), Ser-32
(S32A), Thr-34 (T34A), and Lys-50 (K50A) all failed to inhibit
gp350 binding (Table 2). These data strongly reinforce previ-
ous cell-binding studies that suggested a SCR1-dominant con-
tribution to gp350 attachment and also expand the amount of
surface area of this domain that has been mutated and ana-
lyzed. Only one substitution, Y16A, appeared to exhibit levels
of gp350 binding that were different from that previously ob-
served in the cell-binding study (46) (66.7% in the cell-binding
study and 95.1% in the ELISA) (Table 2).
Three residues were targeted for mutagenesis within the
eight-residue (63-EYFNKYSS-70) linker region connecting
SCR1 and SCR2; Tyr-64, Lys-67, and Tyr-68 each were re-
placed with an alanine residue (Y64A, K67A, and Y68A). Only
the K67A substitution demonstrated any significant effect on
gp350 binding, with an approximately 20% decrease (Fig. 5).
Within SCR2, a total of four residues were selected for mu-
tagenesis screening: Arg-83 (R83A), Thr-86 (T86A), Arg-89
(R89A), and Met-117 (M117A). Arg-83 previously has been sug-
gested to play an important role in gp350 binding and also to be
essential in the interaction between CR2 and its major physiologic
ligand, C3d (17, 39, 46). Of the four alanine substitutions gener-
ated in SCR2, only the R83A and R89A mutants exhibited de-
creased binding affinities for gp350 (Fig. 5).
When mapped onto the crystal structure of CR2 SCR1-2,
the data obtained using the MBP-CR2 SCR1-2 mutants delin-
eates a binding interface that consists of a contiguous positively
charged surface spread over SCR1 and SCR2, with two hot
spots centered around Arg-83 and Arg-89 on SCR2 and Arg-
13, Ser-15, Arg-28, Arg-36, and Lys-41 on SCR1 (Fig. 6) that
are essential for the attachment of gp350.
MBP-CR2 SCR1-2–171 MAb and MBP-CR2 SCR1-2–629
MAb ELISA. The excellent correlation observed between our
cell-binding studies and the ELISA analyses provides proof of
principle that the MBP-CR2 SCR1-2 ELISA is an effective
means of characterizing CR2-ligand interactions. We therefore
utilized our 19 MBP-CR2 SCR1-2 mutants to describe the
structured epitope for the anti-CR2 SCR1-2 MAb 171, which
inhibits the interaction with gp350 as well as all other known
CR2 ligands (1, 13, 46). ELISA revealed that single-site mu-
FIG. 3. Effect of gp350 mutagenesis on wild-type CR2 binding
(ELISA). (A) Alanine substitutions mapped onto a ribbon represen-
tation of the region comprising D1 and D2 of gp350. The scheme used
to color residues represents the percent binding of wild-type MBP-
CR2 SCR1-2 to mutant forms of gp350 (at a concentration of 5 g/ml
of mutant gp350 and 2 g/ml of wild-type MBP-CR2 SCR1-2). The
image in panel B was constructed similarly to that for panel A, except
the molecule has been rotated about the y axis by 60°. N-term, N
terminus.
TABLE 1. Summary of wild-type CR2 binding to mutant
forms of gp350a
gp350
mutation
ELISA Cell-binding assay
% gp350 binding
by MBP-CR2
SCR1-2 (SEM)
Weighting
% gp350-biotin
binding, MFI
(SEM)
Weighting
E21A 65.6 (7.6)  57.6 (3.2) 
D22A 5.2 (0.1)  44.6 (3.4) 
D53A 89.3 (1.1)  90.8 (2.6) 
E119A 101.5 (0.1)  80.4 (5.3) 
Y151A 16.1 (1.5)  57.5 (0.2) 
E155A 28.5 (1.4)  67.6 (3.8) 
Y159A 82.8 (3.4)  94.8 (2.6) 
I160A 10.4 (8.3)  50.1 (5.5) 
W162A 15.7 (8.9)  13.3 (2.7) 
D163A 86.7 (1.4)  83.7 (0.7) 
E201A 63.5 (2.5)  103.9 (3.4) 
D208A 34.5 (2.5)  68.2 (12.3) 
E210A 41.6 (1.2)  63.6 (4.2) 
E214A 98.7 (1.4)  76.2 (0.8) 
D215A 64.4 (1.4)  86.5 (14.4) 
E236A 101.2 (1.1)  90.6 (4.6) 
D296A 10.3 (0.4)  61.4 (2.0) 
a Given are the percentages of the CR2 binding of single-site mutant forms of
gp350 relative to those of wild-type gp350 from both ELISA and cell-binding
analyses. , 90%; , 89.9 to 70%; , 69.9 to 40%; , 39.9 to
20%; , 19.9 to 0%. MFI, mean fluorescent intensity. Data are reported for
concentrations of 2 g/ml of MBP-CR2 SCR1-2 and 5 g/ml of gp350 for the
ELISA study and 5  105 full-length CR2-transfected K562 cells and 5 g/ml of
gp350-biotin for the cell-binding study. Mutants indicated in boldface demon-
strate a greater-than 20% decrease in binding affinities relative to those of
wild-type CR2 in both ELISA and the cell-binding assays. Residues (wild type)
that have been underlined have been defined as active for the purposes of the
soft-docking study.
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tants targeting a patch of residues located within the first
intercysteine region of SCR1 of CR2, comprising Asn-11, Arg-
13, Ser-32, Thr-34, and Arg-36 (N11A, R13A, S32A, T34A,
and R36A), and also a single residue within the linker region
connecting SCR1 and SCR2, Tyr-64 (Y64A), disrupted the
epitope for MAb 171 (Table 3). This epitope overlaps exten-
sively with the binding surface on CR2 described above for
gp350 and also with the previously described binding sites for
C3dg and C3d (17, 46). By contrast, none of these MBP-CR2
SCR1-2 mutants were found to have any deleterious effects on
the binding of a noninhibitory anti-CR2 SCR1-2 MAb, 629
(13). This suggests that the epitope for MAb 629 is located on
a surface discrete from the ligand-binding sites described
above for gp350 and also for the previously characterized C3
fragments C3dg and C3d (Table 3). A single alanine substitu-
tion targeting Tyr-16 (Y16A) demonstrated increased binding
(	150%) to MAb 629 relative to that of wild-type MBP-CR2
SCR1-2.
HADDOCK-derived CR2-gp350 model. The mutagenesis
data for gp350 and CR2 obtained in the current study were
used to generate a series of AIRs that subsequently were
employed by the soft-docking program HADDOCK (8) to
derive a model of the CR2 SCR1-2–gp350 complex. Solvent-
accessible (50% or greater) residues on CR2 and gp350, the
mutation of which disrupts complex formation according to
both our ELISA and cell-binding assays, were designated ac-
tive residues for the docking calculations (Tables 1 and 2).
Starting from the randomly oriented structures of CR2 and
gp350, active residues were used by HADDOCK to direct the
docking process toward the most plausible complex of CR2
and gp350, which also satisfied the data previously recorded
(Fig. 7). A cluster analysis of the resulting 100 water-refined
FIG. 4. K562 cell-binding flow cytometry analysis of the wild-type CR2–mutant gp350-biotin interaction. (A to G) The capacity of wild-type
CR2 SCR1-15-expressing cell populations, which have been labeled with FITC, to bind wild-type or mutant forms of PE-conjugated gp350-biotin.
(A to F) Representative whole-cell populations of K562 erythroleukemia cells expressing wild-type CR2 to bind wild-type (A), D22A (B), Y151A
(C), I160A (D), W162A (E), and D296A (F) forms of gp350. (G) Bar chart of the normalized values of the intermediate CR2-expressing
population (25%) for binding to all 17 gp350-biotin mutants generated in this study. Averages and standard errors of the normalized values for
the mean fluorescence intensity of the intermediate CR2-expressing population (25%) are shown. An asterisk indicates that plate-bound forms of
mutant gp350 also exhibited a decreased ability to bind MBP-CR2 SCR1-2 in the ELISA study. A plus indicates that data are inconsistent with
those observed in the MBP-CR2 SCR1-2 ELISA study (Table 1).
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structures, employing a 1.5-Å cutoff limit, revealed that 99 of
these models fell into a single cluster. For the 100 water-
refined structures analyzed, the backbone root mean square
deviation (RMSD) at the intermolecular interface for all struc-
tures was 1.5 Å (1.9 Å for all backbone atoms in all structures).
The average buried surface area for the 100 water-refined
structures was 2,510
 192 Å2. The structures calculated are in
good agreement with experimental evidence, as determined by
an average of 0.04 AIR violations for 0.5 Å per structure.
Our models of the gp350–CR2-SCR1-2 complex also are
highly structurally uniform and are in broad agreement with
results generated using an incomplete set of AIRs (18). The
backbone interface RMSD values obtained for our model of
the CR2-gp350 complex are consistent with those of other
HADDOCK-derived models of protein complexes that com-
pare favorably with the corresponding atomic resolution struc-
tures (44). Reported in the fourth and fifth rounds of the
critical assessment of the prediction of interactions, these mod-
els exhibited backbone interface RMSD values ranging from
0.3 to 2.0 Å (44). Moreover, the CR2 SCR1-2-binding site on
gp350 is highly plausible, being located within a negatively
charged region on the surface of this molecule that is devoid of
the glycan moieties that cover much of the surface.
DISCUSSION
The interaction between the two N-terminal extracellular
SCR domains of CR2 and the major EBV envelope protein
FIG. 5. MBP-CR2 SCR1-2–gp350 ELISA data targeting residues within CR2 SCR1-2. The ability of mutant forms of MBP-CR2 SCR1-2 to
bind plate-bound wild-type gp350 is shown. Data are shown for R13A, S15P, R28A, R36A, K41A, K50A, K57A, K67A, R83A, and R89A. The
averages and standard errors of the means of the normalized values relative to those for wild-type gp350 binding are given. Data are not shown
for a number of MBP-CR2 SCR1-2 mutants that exhibited wild-type-like levels of binding (20% reduction): L10A, N11A, Y16A, S32A, T34A,
Y64A, Y68A, T86A, and M117A (Table 2).
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gp350 is an integral part of the adsorption of virions onto the
surface of B lymphocytes. Knowledge of the precise nature of
this interaction is required to understand the mechanism
whereby the engagement of the N terminus of CR2 by EBV
progresses to invasion. In the current work, data derived from
single-site mutant forms of both CR2 and gp350 were used to
drive a working model of the CR2-gp350 complex that is con-
sistent with the mutagenesis data. This model also is consistent
with previous experimental data pertaining to EBV-CR2 in-
teractions and with the results of other experiments reported
here in which we have characterized the structured epitope of
a major inhibitory anti-CR2 SCR1-2 MAb.
An effective ELISA was developed that has allowed us, for
the first time, to map out the binding interface for the CR2
SCR1-2–EBV gp350 interaction on both molecules. Our
ELISA data are supported by cell-binding studies in which
PE-conjugated gp350-biotin mutants were incubated with
K562 cells transfected with human CR2 SCR1-15. Indeed, the
FIG. 6. Effect of CR2 mutagenesis on wild-type gp350 binding
(ELISA). (A) Alanine and proline substitutions mapped onto a ribbon
representation of CR2 SCR1-2. The scheme used to color residues
represents the percent binding of wild-type gp350 to mutant forms of
MBP-CR2 SCR1-2 (at a concentration of 5 g/ml gp350 and 2 g/ml
of mutant MBP-CR2 SCR1-2). The image in panel B was constructed
similarly to that for panel A, except the molecule has been rotated
about the y axis by 90°. N-term, N terminus; C-term, C terminus.
FIG. 7. Ribbon representative of the HADDOCK-derived model
of the CR2-gp350 complex generated utilizing the mutagenesis data
described in Tables 1 and 2 and the crystal structures of CR2 SCR1-2
and gp350.
TABLE 2. Summary of wild-type or mutant MBP-CR2 SCR1-2–
gp350 binding ELISA dataa
CR2
mutation
ELISA Cell-binding assayb
% gp350 binding
by MBP-CR2
SCR1-2 (SEM)
Weighting
% gp350-biotin
binding, MFI
(SEM)b
Weighting
L10A 98.2 (5.1)  NA NA
N11A 93.6 (0.6)  112.6 (11.6) 
R13A 4.9 (0.1)  7.0 (0.4) 
S15P 5.8 (0.5)  5.4 (0.4) 
Y16A 95.1 (0.1)  66.7 (4.0) 
R28A 58.0 (5.6)  21.9 (1.8) 
S32A 94.8 (1.0)  108 (12.9) 
T34A 106.6 (5.4)  NA NA
R36A 52.2 (3.1)  29 (4.8) 
K41A 13.6 (0.7)  20.8 (1.8) 
K50A 70.8 (11.4)c c 59.2 (1.9)c c
K57A 70.7 (2.3)  36.5 (3.7) 
Y64A 93.6 (1.0)  84.5 (3.4) 
K67A 79.5 (7.4)  42.1 (3.9) 
Y68A 87.5 (2.7)  111.4 (7.4) 
R83A 32.1 (0.8)  32.9 (4.9) 
T86A 91.9 (0.5)  NA NA
R89A 56.1 (0.7)  NA NA
M117A 96.5 (4.1)  NA NA
a Given are percentages of gp350 binding to mutant CR2 relative to that of
wild-type CR2. , 90%; , 89.9 to 70%; , 69.9 to 40%;, 39.9 to
20%; , 19.9 to 0%.
b Binding data and weighting were obtained from a previously reported cell-
binding analysis of the CR2-gp350 binding interaction (46). NA, not applicable.
Mutants indicated in boldface demonstrate a greater than 20% decrease in
binding affinities relative to that of wild-type gp350 in both ELISA and the
cell-binding assay (where available).
c While the K50A mutant demonstrates a reduction in binding at the protein
concentrations described in this table, at other values recorded for both the
ELISA and cell-binding analyses, K50A binding approximates that of wild-type
CR2 (Fig. 5) (1, 46). Residues (wild type) that have been underlined have been
defined as active to drive the soft-docking study.
TABLE 3. Summary of wild-type or mutant MBP-CR2 SCR1-2
binding to the anti-CR2 SCR1-2 MAbs 171 and 629a
CR2
mutation
MAb 171 MAb 629
% Binding
(SEM) Weighting
% Binding
(SEM) Weighting
L10A 94.7 (3.2)  113.2 (6.4) 
N11A 24.1 (1.4)  87.5 (2.1) 
R13A 15.6 (2.1)  108.1 (0.8) 
S15P 108.5 (1.6)  91.7 (7.3) 
Y16A 81.4 (3.7)  154.4 (4.0) 
R28A 103.8 (1.7)  103.1 (1.8) 
S32A 77.5 (8.9)  117.8 (3.4) 
T34A 12.4 (1.4)  84.9 (5.8) 
R36A 19.8 (1.7)  113.9 (1.5) 
K41A 97.3 (1.7)  97.5 (0.8) 
K50A 94.4 (3.5)  87.5 (3.2) 
K57A 91.9 (0.8)  85.5 (0.7) 
Y64A 5.8 (0.1)  82.0 (1.5) 
K67A 87.7 (3.2)  107.2 (4.5) 
Y68A 92.1 (4.8)  102.3 (4.1) 
R83A 96.9 (2.4)  94.4 (3.9) 
T86A 89.6 (5.2)  85.6 (3.3) 
R89A 93.9 (7.8)  87.7 (2.1) 
M117A 97.2 (4.1)  113.8 (2.9) 
a The weighting used is the same as that described above for Tables 1 and 2.
Mutants indicated in boldface demonstrate a greater than 20% decrease in
binding affinities relative to those of wild-type CR2.
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cell-binding assays delineate an identical CR2-binding surface
on gp350, with only two mutants, E201A and D215A, behaving
differently from what would be expected from the ELISA. Both
of these point mutants exhibited wild-type levels of binding in
the cell-binding assay and approximately 60 to 70% activity by
ELISA. Interestingly, Asp-215 is remote from the major CR2
interaction center within gp350, and it is likely that Glu-201
and Asp-215 play only a peripheral or negligible role in the
docking of gp350. A likely explanation for any observed dif-
ferences in binding utilizing the two methodologies employed
in this study may be attributable to a lower sensitivity of the
cell-binding approach or to the differing solution conditions
used for the experiments.
Of the 17 single-site gp350 mutants generated in the current
study, targeting D1, D2, and linker-1 of gp350, 10 consistently
exhibited compromised ability to bind CR2: E21A, D22A,
Y151A, E155A, I160A, W162A, E201A, D208A, D210A, and
D296A. The remaining seven (D53A, E119A, Y159A, D163A,
E214A, D215A, and E236A) demonstrated wild-type-like or
only slightly reduced levels of gp350 binding. When mapped
onto the gp350 crystal structure, the mutations that affect bind-
ing correspond to a predominantly electronegative binding sur-
face within D1 and D2 (Fig. 3); this appears to be complemen-
tary to the positively charged binding region identified in
SCR1-2 of CR2.
Strikingly, both ELISA and cell-binding data identify a sig-
nificant additional contribution from residues within the gp350
D1-D2 linker. A total of five point mutations were generated
within the linker-1 region, three of which appeared to critically
affect CR2 binding (E155A, I160A, and W162A) and two of
which did not (Y159A and D163A). In support of these data,
the side chains of Glu-155, Ile-160, and Trp-162 are oriented
toward the putative binding site delineated by Glu-21, Asp-22,
Tyr-151, Asp-208, Glu-210, and Asp-296 in the gp350 crystal
structure, while the side chains of Tyr-159 and Asp-163 are
oriented away from this region (Fig. 3). Taking these findings
together, it is unlikely that the reduction in binding observed
for those deleterious mutations targeting the D1-D2 linker are
the result of a significant reorientation. From the crystal struc-
ture of gp350, Glu-155, Ile-160, and Trp-162 all possess side
chain solvent accessibilities of greater than 50% (according to
NACCESS) and do not appear to significantly contribute to
the overall fold of the gp350 molecule.
With regard to delineating the gp350-binding site on CR2,
19 single-site CR2 SCR1-2 mutants were engineered as soluble
recombinant MBP fusion proteins, and binding was measured
using the ELISA described above. The data obtained were
considered in conjunction with a previously published study in
which wild-type or mutant full-length CR2-transfected K562
cells were incubated with wild-type gp350 and binding inter-
actions assessed by flow cytometry (46). The ELISA-derived
data delineate a contiguous positively charged gp350-binding
surface upon CR2 that is consistent with the cell-binding assay
(46). Arg-83 and Arg-89 on SCR2 both play important roles in
the ligation of gp350. Of the other mutations within SCR2,
Thr-86 is in close proximity to the putative gp350-binding site
outlined in Fig. 6, but T86A binds gp350 with wild-type-like
affinity. Notably, the side chain of this amino acid residue
extends downwards and away from the plane formed by resi-
dues 83 and 89. Met-117, on the other hand, is located on the
opposite face of the domain and, unsurprisingly, the M117A
mutant binds gp350 with the same affinity as wild-type CR2.
Point mutations that target CR2-SCR1 indicate that residues
Arg-13, Ser-15, Arg-28, Arg-36, and Lys-41 play an important
role in the interaction between CR2 and gp350, consistent with
previous work (46). The R13A, S15P, and K41A mutations, in
particular, have a deleterious effect on gp350 binding. The
S15P substitution is likely to induce a localized structural per-
turbation of the viral binding surface on CR2, while the R13A
and K41A mutations (as well as the R36A and R28A substi-
tutions) are likely to interfere with the well-established charge
dependence of the CR2-gp350 interaction (12, 36). In previous
work, R13A, S15P, R28A, R36A, K41A, K57A, K67A, and
R83A MBP-CR2 SCR1-2 demonstrated reduced or zero ca-
pacity to pull down concentrated intact virus; this supports the
case for the recombinant gp350-binding interface identified on
CR2 SCR1-2, reflecting that of intact gp350/220 expressed on
the surface of enveloped EBV virions (46).
It has previously been suggested that the available crystal
structures of CR2 SCR1-2 do not reflect the physiological
orientation of the two amino-terminal domains with respect to
one another. Both crystallized forms of the protein were ex-
pressed using Pichia pastoris and then deglycosylated prior to
crystallization. Prota et al. suggested that the presence of the
nonnative N-glycan moiety attached to Asn-107 would steri-
cally force the two SCR domains apart in the native protein
(34). We have demonstrated in the current study, however,
that the data obtained using E. coli-derived recombinant MBP-
CR2 SCR1-2, with no posttranslational processing, are similar
to those obtained from a K562 mammalian cell expression
system that produced glycosylated protein (5). These data sug-
gest that glycosylation within the two N-terminal domains of
human CR2 does not significantly contribute to its structure-
function relationships. With regard to the CR2 SCR1-2 archi-
tecture under solution conditions, an analytical ultracentrifu-
gation and solution-scattering study, carried out in conjunction
with molecular modeling by Perkins and coworkers, suggested
that the domain packing of CR2 SCR1-2 is more extended
than that observed in the available crystal elucidations, but that
the molecule still adopts an overall constrained V-shaped con-
formation (11).
Further evidence that the gp350-binding site located within
SCR1 of CR2 identified by our mutagenesis studies is indeed a
primary site of EBV attachment is provided by our mutagen-
esis screening of the MAb 171 and MAb 629 epitopes on CR2
SCR1-2. MAb 171 is an effective inhibitor of all CR2-ligand
interactions (1, 13, 46). Our data demonstrate that the struc-
tured epitope for MAb 171 is located within a patch of residues
within the first intercysteine region of SCR1 and also the initial
part of the eight-residue linker region connecting SCR1 and
SCR2 (Asn-11, Arg-13, Ser-32, Thr-34, Arg-36, and Tyr-64)
(Table 3). Residues important in the binding of 171 MAb
overlap directly with residues that we have identified as being
present at the CR2-gp350 interface (Table 2) (46) and that also
have been shown to play a significant role in C3d/C3dg ligation
(Arg-13 and Arg-36) by both site-directed mutagenesis (17)
and, more recently, heteronuclear nuclear magnetic resonance
spectroscopy (J. M. Kovacs, J. P. Hannan, E. Z. Eissenmesser,
and V. M. Holers, unpublished data). Our data delineating the
MAb 171 structured epitope differ significantly from those
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obtained by overlapping peptide-based approaches, which
have demarcated the linear epitope of MAb 171 to residues
86-TPYRH-90 located within SCR2 of CR2 (13). However, it
is likely that the 171 epitope delineated by our mutagenesis
mapping is a better reflection of the experimentally defined
inhibitory properties that have been described for MAb 171,
since all competition studies have utilized folded proteins ex-
pressed either on cell surfaces or as soluble recombinant mol-
ecules (1, 13, 46). Notably, of the 86-TPYRH-90 sequence
described by the use of mimotope sequences displayed on pins,
Tyr-88 and His-90 are buried beneath the protein surface in
both of the available crystal structures of CR2 (34, 39). Inter-
estingly, when our mutant MBP-CR2 SCR1-2 library was em-
ployed to screen a control noninhibitory anti-CR2 antibody,
MAb 629, none of our mutants targeting the CR2 ligand-
binding sites were found to disrupt binding to any significant
extent (Table 3). It therefore is likely that the structured
epitope for 629 is located on a surface discrete from the char-
acterized gp350 and C3d/C3dg binding sites (Table 3).
A goal of assembling this extensive set of mutagenesis data
was to drive a plausible model of the CR2-gp350 complex using
a molecular docking algorithm. Our best-fit model of the com-
plex generated by HADDOCK locates the CR2 SCR1-2 bind-
ing site within a glycan-free area of gp350. These data are
consistent with previous studies demonstrating that the numer-
ous N-linked glycans coating gp350 do not play a significant
role in the binding interaction between CR2 and gp350 (40).
The nature of the binding pocket for CR2 SCR1-2 observed
within gp350 is consistent with a conformation of the CR2
SCR1-2 molecule in which the domain orientation approxi-
mates a V-shaped topography. Whether the two SCR domains
make contact with each other, as reflected in the two crystal-
lographic studies (34, 39), or adopt a more open but still
V-shaped conformation, as observed in solution studies, does
not have a significant bearing on the model (11). The complex
predicted by HADDOCK aligns SCR1 of CR2 with the elec-
tronegative region on gp350 delineated primarily by Glu-201,
Asp-208, Glu-210, and Asp-296 and SCR2 oriented toward
Glu-21, Asp-22, and Glu-155. Another notable feature of the
interaction is the presence of aromatic and nonpolar residues
dominating the center of the complex. In all, our CR2-gp350
model appears to describe a classic protein-protein interaction,
whereupon opposite charges on each molecule direct complex
initiation and formation and surround a hydrophobic/nonpolar
core that is buried within the complex.
In summary, we have carried out a site-directed mutagenesis
study to provide the basis of a structural understanding of the
initial contact that occurs between EBV and B lymphocytes.
We have extensively characterized the gp350-binding site on
CR2 and compared this binding site to the structured epitope
of an effective inhibitory anti-CR2 MAb, 171. Furthermore, we
have provided the first detailed delineation of the CR2-binding
site on gp350, describing a predominantly negatively charged
binding surface within the two N-terminal domains of gp350,
and identified additional side chain contributions from the
linker region between them. Furthermore, we have identified
nonpolar and hydrophobic residues on gp350 that are neces-
sary for efficient binding. Finally, our mutagenesis data have
been used as the basis for generating a testable constraint-
derived model of the CR2-gp350 complex. In toto, these data
provide a structural basis for developing inhibitors of this im-
portant virus-receptor interaction.
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